Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone: Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder (SWIFT)

Status: Completed
Location: See all (6) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study compares two methods of initiating treatment with extended-release naltrexone (XR-NTX) when implemented at community-based inpatient or residential programs. The primary goal of this hybrid effectiveness-implementation study is to determine whether the Rapid Method (5-7 day long) is non-inferior to a Standard Method (13-day long) on the primary effectiveness outcome of successful initiation of XR-NTX (receiving the first injection). Secondary objectives include comparing Rapid versus Standard method on: time from admission to first dose of XR-NTX and time to dropout, craving, withdrawal severity, retention, abstinence, and safety measures, as measured during the inpatient induction process and the first two months of post-induction XR-NTX maintenance. Other exploratory outcomes include predictors of initiation success, and economic analyses. The implementation goal is to operationalize an implementation facilitation strategy that will be used to train clinical sites on the XR-NTX initiation method, to capture fidelity to the rapid induction process, and to study barriers and facilitators to implementation and refine the implementation facilitation strategy accordingly.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• 18 years of age or older.

• Meets current Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for opioid use disorder.

• Seeking treatment for opioid use disorder, willing to accept treatment with XR- NTX and, in the judgment of the treating physician, is a good candidate for naltrexone- based treatment.

• Willing and able to provide written informed consent.

• Able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study.

• If female of childbearing potential, willing to practice an effective method of birth control for the duration of participation in the study.

Locations
United States
Florida
Aspire Health Partners
Orlando
Maryland
Avery Road Treatment Center
Rockville
Missouri
Gibson Recovery Center, Inc.
Cape Girardeau
New York
Stony Brook Eastern Long Island Hospital
Greenport
Oregon
Adapt
Roseburg
Texas
Nexus Recovery Center, Inc.
Dallas
Time Frame
Start Date: 2021-03-16
Completion Date: 2022-12-21
Participants
Target number of participants: 415
Treatments
Active_comparator: Standard Induction Method
The Standard Method (13-day long) includes 5-days of buprenorphine taper followed by 7-day washout period
Experimental: Rapid Induction Method
The Rapid Method includes one day of buprenorphine followed by a day of washout and 3-4 days of oral naltrexone titration with adjunctive medications
Related Therapeutic Areas
Sponsors
Collaborators: National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Leads: New York State Psychiatric Institute

This content was sourced from clinicaltrials.gov

Similar Clinical Trials